Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.0
3.4
Journals
Life
Special Issues
Contemporary Therapeutic Strategies for Solid Tumors
share announcement

Contemporary Therapeutic Strategies for Solid Tumors

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".

Deadline for manuscript submissions: 26 July 2026 | Viewed by 3272

Special Issue Editor

Dr. Chohao Lee

E-Mail Website
Guest Editor
Triservice General Hospital Taiwan, National Defense Medical Center, Taipei, Taiwan
Interests: hematologic malignancies; stem cell transplantation; immunotherapy; CAR-T cell therapy; multiple myeloma; leukemia and lymphoma; precision medicine; novel therapeutics; hematopoietic stem cells; drug resistance in cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue addresses contemporary therapeutic strategies and survival outcomes in severe diseases, with a primary focus on solid tumors. As advances in cancer treatment continue to evolve rapidly, there is a critical need to evaluate both innovative therapeutic approaches and their impact on patient survival and long-term outcomes.

We invite original research articles, systematic reviews, meta-analyses, and clinical studies that examine cutting-edge treatment modalities and survival analysis across a diverse range of solid tumors, including but not limited to nasopharyngeal carcinoma, rectal cancer, breast cancer, lung cancer, gastric cancer, and hepatocellular carcinoma. This Special Issue particularly welcomes submissions exploring targeted therapy, immunotherapy, precision medicine, combination treatment regimens, and emerging cellular therapies for solid tumors, alongside comprehensive survival analyses that provide insights into prognostic factors and treatment efficacy.

The scope encompasses both prospective and retrospective studies that evaluate treatment outcomes for solid tumors, comparative effectiveness research, real-world evidence, and translational studies bridging laboratory discoveries to clinical applications. We encourage investigations into treatment-related survival benefits, quality of life assessments, biomarker-guided therapeutic decisions, and strategies to overcome treatment resistance in the context of solid malignancies.

This Special Issue aims to serve as a comprehensive resource for clinical physicians, oncologists, and researchers seeking to understand current best practices and emerging paradigms in the management of solid tumors. By integrating therapeutic innovation with rigorous survival analysis, we hope to contribute meaningful insights that will enhance clinical decision-making and ultimately improve patient outcomes in the face of these life-threatening malignancies.

Dr. Chohao Lee
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • therapeutic strategies
  • survival analysis
  • solid tumors
  • cancer treatment
  • targeted therapy
  • immunotherapy
  • precision medicine
  • clinical outcomes
  • prognostic factors

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

17 pages, 2529 KB  
Article
Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer
by Min-Chi Cheng, Po-Huang Chen, Yu-Guang Chen, Shiue-Wei Lai, Jia-Hong Chen, Ming-Shen Dai and Ping-Ying Chang
Life 2026, 16(4), 564; https://doi.org/10.3390/life16040564 - 30 Mar 2026
Viewed by 574
Abstract
Background: The optimal sequencing of regorafenib and trifluridine/tipiracil (FTD/TPI) in refractory metastatic colorectal cancer (mCRC) remains uncertain, particularly in Asian populations. Methods: We retrospectively analyzed 110 patients with mCRC who sequentially received both agents between 2011 and 2025. Patients were categorized into regorafenib [...] Read more.
Background: The optimal sequencing of regorafenib and trifluridine/tipiracil (FTD/TPI) in refractory metastatic colorectal cancer (mCRC) remains uncertain, particularly in Asian populations. Methods: We retrospectively analyzed 110 patients with mCRC who sequentially received both agents between 2011 and 2025. Patients were categorized into regorafenib followed by FTD/TPI (Rego → FTD/TPI, n = 88) and FTD/TPI followed by regorafenib (FTD/TPI → Rego, n = 22). Co-primary endpoints were time to treatment discontinuation (TTD) and overall survival (OS). Propensity score-based weighting methods, including stabilized inverse probability of treatment weighting (primary analysis), were used to adjust for baseline imbalances. Multivariable Cox regression was performed as a sensitivity analysis. Results: No statistically significant differences were observed between treatment sequences. In the primary analysis, the hazard ratio (HR) for TTD was 1.01 (95% CI 0.71–1.43), and for OS was 1.19 (95% CI 0.67–2.12), with FTD/TPI → Rego as reference. Median TTD was 6.8 versus 8.9 months, and median OS was 14.6 versus 20.2 months, respectively. Conclusions: Clinical outcomes were comparable regardless of treatment order, supporting individualized sequencing decisions in refractory mCRC. Full article
(This article belongs to the Special Issue Contemporary Therapeutic Strategies for Solid Tumors)
►▼ Show Figures

Figure 1

12 pages, 873 KB  
Article
Comparative Effectiveness and Safety of Denosumab Versus Bisphosphonates in Elderly Patients with Cancer Bone Metastases: A Target Trial Emulation Study
by Che-Wei Liu, Shun-Neng Hsu, Shao-Hsuan Chang, Wei-Cheng Chang, Chun-Liang Hsu, Hsin-Yu Chen, Po-Huang Chen and Cho-Hao Lee
Life 2026, 16(2), 346; https://doi.org/10.3390/life16020346 - 17 Feb 2026
Viewed by 1138
Abstract
Objective: Bone-modifying agents (BMA) are central to the prevention of skeletal-related events (SREs) in patients with cancer bone metastases, yet evidence guiding agent selection in very old patients remains limited. This study aimed to compare the effectiveness and safety of Denosumab versus bisphosphonates [...] Read more.
Objective: Bone-modifying agents (BMA) are central to the prevention of skeletal-related events (SREs) in patients with cancer bone metastases, yet evidence guiding agent selection in very old patients remains limited. This study aimed to compare the effectiveness and safety of Denosumab versus bisphosphonates in patients aged ≥75 years with solid tumour-related bone metastases using a target trial emulation framework. Methods: We conducted a retrospective cohort study using the TriNetX Global Collaborative Network to emulate a hypothetical randomised trial. Patients aged ≥75 years with solid tumour-related bone metastases initiating Denosumab or bisphosphonates were included. After 1:1 propensity score matching (PSM), 10,662 patients were analysed in each treatment group. The primary outcome was time to first SRE. Secondary outcomes included individual SRE components, all-cause mortality, and safety events. Results: Among 21,324 matched patients (mean age, 75.6 years), bisphosphonate use was associated with a higher risk of SREs compared with Denosumab (hazard ratio [HR], 1.15; 95% CI, 1.06–1.25). The excess risk was driven by pathological fractures (HR, 1.28; 95% CI, 1.10–1.49), whereas other SRE components did not differ significantly. All-cause mortality was higher among bisphosphonate users (HR, 1.41; 95% CI, 1.33–1.49, p < 0.001). Hypocalcaemia occurred more frequently with Denosumab (5.7% vs. 2.4%), while risks of acute kidney injury and end-stage renal disease (ESRD) were similar. Findings were consistent across sensitivity and subgroup analyses. Conclusions: In patients aged ≥75 years with solid tumour-related bone metastases, Denosumab was associated with lower risks of skeletal-related events—particularly pathological fractures—and reduced all-cause mortality compared with bisphosphonates. These results extend randomised trial evidence to a clinically vulnerable population and support Denosumab as a preferred BMA in older adults. Full article
(This article belongs to the Special Issue Contemporary Therapeutic Strategies for Solid Tumors)
►▼ Show Figures

Figure 1

14 pages, 1246 KB  
Article
Adjuvant Tegafur-Uracil Improves Survival in Low-Risk, Mismatch Repair Proficient Stage IIA Colon Cancer: A Propensity Score-Matched Analysis
by Min-Chi Cheng, Hsu-Lin Lee, Shiue-Wei Lai, Jia-Hong Chen and Po-Huang Chen
Life 2025, 15(12), 1930; https://doi.org/10.3390/life15121930 - 17 Dec 2025
Cited by 1 | Viewed by 733
Abstract
Background: The benefit of adjuvant chemotherapy for low-risk, mismatch repair proficient (pMMR) stage IIA colon cancer is uncertain. Surveillance is standard, but some patients relapse. Tegafur-uracil (UFT) is a low-toxicity oral option that may offer benefit; Methods: This retrospective study included [...] Read more.
Background: The benefit of adjuvant chemotherapy for low-risk, mismatch repair proficient (pMMR) stage IIA colon cancer is uncertain. Surveillance is standard, but some patients relapse. Tegafur-uracil (UFT) is a low-toxicity oral option that may offer benefit; Methods: This retrospective study included patients with resected low-risk, pMMR stage IIA colon cancer (2013–2022). Patients receiving ≥5 postoperative UFT prescriptions were compared with those under surveillance. Propensity score matching (1:1) was applied, and disease-free survival (DFS) and overall survival (OS) were analyzed using Kaplan–Meier and Cox models with sensitivity analyses.; Results: Among 279 eligible patients, 71 matched pairs were analyzed. UFT reduced the risk of recurrence or death by 57% (DFS HR = 0.43, 95% CI 0.25–0.75, p = 0.002) and mortality by 62% (OS HR = 0.38, 95% CI 0.21–0.68, p < 0.001); Conclusions: UFT improved DFS and OS in low-risk pMMR stage IIA colon cancer, suggesting surveillance alone may undertreat some patients. Prospective trials are warranted. Full article
(This article belongs to the Special Issue Contemporary Therapeutic Strategies for Solid Tumors)
►▼ Show Figures

Figure 1

Review

Jump to: Research

24 pages, 2606 KB  
Review
Therapeutic Innovations in Nasopharyngeal Carcinoma: Current Strategies and Emerging Perspectives
by Weronika Pająk, Jakub Kleinrok, Joanna Pec, Adrian Orzechowski, Jakub Drabko, Ryszard Sitarz, Alicja Forma, Adam Brachet, Barbara Teresińska and Jacek Baj
Life 2026, 16(5), 764; https://doi.org/10.3390/life16050764 - 2 May 2026
Viewed by 313
Abstract
Nasopharyngeal carcinoma (NPC) presents unique clinical and biological characteristics that distinguish it from other head and neck malignancies. It poses a great therapeutic challenge for many specialists. It is associated with Epstein–Barr virus (EBV) infection, genetic predisposition, and environmental risk factors. With advancements [...] Read more.
Nasopharyngeal carcinoma (NPC) presents unique clinical and biological characteristics that distinguish it from other head and neck malignancies. It poses a great therapeutic challenge for many specialists. It is associated with Epstein–Barr virus (EBV) infection, genetic predisposition, and environmental risk factors. With advancements in radiotherapy and systemic therapy, new treatment options have emerged. We want to focus on contemporary therapeutic strategies for NPC, emphasizing breakthroughs in intensity-modulated radiotherapy (IMRT), chemoradiotherapy, targeted therapy, immunotherapy, and emerging cellular therapies. By integrating recent discoveries with clinical evidence, we aim to provide state-of-the-art information, along with a comprehensive understanding of current best practices, emerging treatments, and critical prognostic determinants in NPC. Full article
(This article belongs to the Special Issue Contemporary Therapeutic Strategies for Solid Tumors)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop